Loading...
XOSL
CONTX
Market cap44mUSD
Apr 30, Last price  
5.95NOK
1D
-0.34%
1Q
15.31%
Jan 2017
20.20%
Name

ContextVision AB

Chart & Performance

D1W1MN
P/E
17.32
P/S
3.27
EPS
0.32
Div Yield, %
—
Shrs. gr., 5y
-0.10%
Rev. gr., 5y
6.51%
Revenues
131m
-1.46%
56,059,00051,951,00069,041,00071,091,00054,731,00053,412,00058,366,00067,115,00061,277,00064,398,00072,237,00081,917,00080,512,00090,903,00095,312,00094,746,00098,098,000117,824,000132,602,000130,670,000
Net income
25m
-24.60%
11,671,0006,165,00020,311,00020,197,000-8,252,000-3,298,0003,578,000620,0004,880,0005,421,0005,338,0004,253,000-1,706,000-1,179,0007,398,00012,080,00034,884,00028,791,00032,729,00024,679,000
CFO
33m
-26.40%
23,744193,00024,554,00021,964,000-9,557,00013,180,0007,734,0008,454,0007,663,00010,373,0009,156,0009,527,0001,948,0005,119,00025,076,00022,315,0009,473,00025,889,00044,748,00032,936,000
Dividend
Nov 02, 20230.1506 NOK/sh
Earnings
May 06, 2025

Profile

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
URL
https://www.contextvision.com/
IPO date
Mar 06, 1997
Employees
36
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
130,670
-1.46%
132,602
12.54%
117,824
20.11%
Cost of revenue
3,342
68,622
(1,269)
Unusual Expense (Income)
NOPBT
127,328
63,980
119,093
NOPBT Margin
97.44%
48.25%
101.08%
Operating Taxes
6,684
8,534
7,726
Tax Rate
5.25%
13.34%
6.49%
NOPAT
120,644
55,446
111,367
Net income
24,679
-24.60%
32,729
13.68%
28,791
-17.47%
Dividends
(23,210)
Dividend yield
3.90%
Proceeds from repurchase of equity
(7,851)
(500)
BB yield
1.85%
0.07%
Debt
Debt current
3,013
3,668
2,546
Long-term debt
17,929
6,694
6,308
Deferred revenue
Other long-term liabilities
447
1,000
Net debt
(53,428)
(47,489)
(31,716)
Cash flow
Cash from operating activities
32,936
44,748
25,889
CAPEX
(3,651)
(703)
(4,828)
Cash from investing activities
(4,829)
(813)
(5,300)
Cash from financing activities
(11,881)
(27,649)
(25,662)
FCF
115,006
45,075
78,597
Balance
Cash
74,370
57,851
40,570
Long term investments
Excess cash
67,836
51,221
34,679
Stockholders' equity
74,961
64,301
Invested Capital
104,728
32,232
28,599
ROIC
176.17%
182.29%
411.37%
ROCE
121.33%
76.67%
187.77%
EV
Common stock shares outstanding
77,368
77,368
77,368
Price
5.50
-28.57%
7.70
-15.75%
9.14
-44.61%
Market cap
425,521
-28.57%
595,730
-15.75%
707,139
-44.61%
EV
372,093
548,241
675,423
EBITDA
135,961
72,814
127,773
EV/EBITDA
2.74
7.53
5.29
Interest
204
214
199
Interest/NOPBT
0.16%
0.33%
0.17%